The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

New developments in molecular MRD assessment in AML

Sep 16, 2020

The virtual AML Hub Satellite Symposiumat the 46 thAnnual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of expertsto discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Christian Thiede, Technical University of Dresden, Dresden, DE, presented the topic ‘New developments in molecular MRD assessment in AML.’

Professor Christian Thiede outlines the recently published European LeukemiaNet (ELN) Working Party recommendations for molecular assessment of MRD in AML. Then, he highlights the benefits of using next-generation sequencing (NGS) for MRD detection. Very recent developments, such as NGS of sorted cells and single cell sequencing, could represent highly sensitive and data-rich options for future molecular MRD assessment in AML.

The first AML Hub Satellite Symposium: Watch here!

Welcome to the AML Hub Satellite Symposium.

Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of molecular MRD assessment.